Ascendis Pharma A/S (NASDAQ:ASND) Receives $304.95 Average Target Price from Brokerages

Shares of Ascendis Pharma A/S (NASDAQ:ASND) have received a consensus recommendation of “Buy” from the twenty analysts that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold rating, seventeen have given a buy rating and two have issued a strong buy rating on the company. The average 1 year price target among brokerages that have covered the stock in the last year is $310.05.

Several research firms recently issued reports on ASND. Barclays dropped their target price on shares of Ascendis Pharma A/S from $345.00 to $329.00 and set an “overweight” rating on the stock in a report on Friday, August 14th. Evercore restated an “outperform” rating and set a $329.00 price objective on shares of Ascendis Pharma A/S in a report on Friday, May 15th. TD Cowen increased their price objective on Ascendis Pharma A/S from $325.00 to $341.00 and gave the stock a “buy” rating in a research note on Friday, August 14th. Royal Bank Of Canada raised their price target on shares of Ascendis Pharma A/S from $280.00 to $290.00 and gave the company an “outperform” rating in a research report on Friday, August 14th. Finally, Wells Fargo & Company cut their price target on shares of Ascendis Pharma A/S from $330.00 to $326.00 and set an “overweight” rating on the stock in a report on Friday, May 8th.

Insider Activity at Ascendis Pharma A/S

In other news, Director Jean-Jacques Bienaimé purchased 2,000 shares of the business’s stock in a transaction dated Friday, August 14th. The stock was bought at an average price of $246.33 per share, for a total transaction of $492,660.00. Following the purchase, the director owned 2,900 shares of the company’s stock, valued at $714,357. The trade was a 222.22% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 40.00% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Ascendis Pharma A/S

Hedge funds and other institutional investors have recently modified their holdings of the stock. Rhumbline Advisers raised its position in shares of Ascendis Pharma A/S by 4.0% in the second quarter. Rhumbline Advisers now owns 1,441 shares of the biotechnology company’s stock worth $249,000 after buying an additional 55 shares in the last quarter. Personal CFO Solutions LLC lifted its position in Ascendis Pharma A/S by 4.4% in the 1st quarter. Personal CFO Solutions LLC now owns 1,519 shares of the biotechnology company’s stock worth $347,000 after buying an additional 64 shares during the last quarter. EverSource Wealth Advisors LLC lifted its position in Ascendis Pharma A/S by 34.0% in the 1st quarter. EverSource Wealth Advisors LLC now owns 272 shares of the biotechnology company’s stock worth $62,000 after buying an additional 69 shares during the last quarter. Farther Finance Advisors LLC boosted its stake in Ascendis Pharma A/S by 15.1% in the fourth quarter. Farther Finance Advisors LLC now owns 550 shares of the biotechnology company’s stock worth $117,000 after buying an additional 72 shares in the last quarter. Finally, GW&K Investment Management LLC boosted its stake in Ascendis Pharma A/S by 75.2% in the fourth quarter. GW&K Investment Management LLC now owns 226 shares of the biotechnology company’s stock worth $48,000 after buying an additional 97 shares in the last quarter.

Ascendis Pharma A/S Price Performance

ASND stock opened at $271.12 on Tuesday. The company has a market capitalization of $16.91 billion, a P/E ratio of 21.03 and a beta of 0.35. Ascendis Pharma A/S has a 52-week low of $186.05 and a 52-week high of $282.15. The company has a fifty day moving average price of $257.65 and a 200-day moving average price of $240.48. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.32 and a current ratio of 2.99.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings results on Friday, August 14th. The biotechnology company reported $1.03 EPS for the quarter, missing analysts’ consensus estimates of $1.71 by ($0.68). Ascendis Pharma A/S had a net margin of 70.99% and a return on equity of 32.54%. The company had revenue of $387.22 million during the quarter, compared to the consensus estimate of $376.75 million. As a group, equities analysts expect that Ascendis Pharma A/S will post 5.99 EPS for the current year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.